TISSUE PLASMINOGEN ACTIVATOR MARKET ANALYSIS

Market Challenges And Opportunities

Global Tissue Plasminogen Activator Market – Drivers

• Increasing Incidence of Stroke: Tissue plasminogen activator (tPA) is an enzyme that is associated with the disintegration of blood clots. It is a serine protease present in endothelial cells.The conversion of plasminogen to plasmin is catalyzed with the help of serine protease.  Serine protease is a major enzyme for clot disintegration. Tissue plasminogen activator is the first and only drug approved by the U.S. FDA in 1996 for the treatment of acute ischemic stroke. Increasing incidence of stroke is expected to drive the market growth during the forecast period.For instance, according to the World Health Organization, in October 2022, as per the Global Stroke Factsheet 2022, the lifetime risk of an individual suffering from a stroke has grown by 50% in the previous 17 years, and one in every four persons is now expected to have a stroke in their lifetime. The most remarkable fact is that lower and lower-middle-income nations bear the majority of the global stroke burden (86% of stroke fatalities and 89% of DALYs).
• Technological Advancements: Various research institutes and market players are focusing on developing advanced treatment by using tissue plasminogen activators for treatment of stokes, and other, and this is expected to drive the global tissue plasminogen activator market growth over forecast period. For instance, in June 2021, Imperial College London, U.K. researchers stated that by encasing tissue plasminogen activator (tPA) in newly developed small capsules, it may be targeted more specifically to hazardous blood clots with enhanced circulation time. The nanocapsules were developed by the researchers to adhere to active platelets in thrombi, release the tPA payload, and disintegrate clots.

Global Tissue Plasminogen Activator Market: Restraint

• Termination of Clinical Trials: Market players are terminating the clinical trials of tissue plasminogen activator, and this is expected to hinder the market growth over forecast period. In July 2023, F. Hoffmann-La Roche AG or Roche, a global healthcare company, announced that it had removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The discontinuations came as Roche admitted that it needs to bolster its late-stage pipeline after a series of setbacks for projects such as breast cancer therapies and others.